Exocrine Pancreatic Insufficiency
Exocrine Pancreatic Insufficiency Market

Exocrine Pancreatic Insufficiency (EPI) refers to the presence of maldigestion and malabsorption of nutrients. It is a result of the direct loss of functional parenchyma and /or secondarily impaired exocrine pancreatic function and insufficient pancreatic enzyme activity.


The causes of EPI are numerous and are not necessarily limited to reduced levels of enzyme production. The condition also may stem from a relative reduction in functioning enzymes reaching the intestinal chyme mixture during digestion; this may result from pancreatic enzyme secretions being inhibited, inactivated by inappropriately low (acidic) pH and mixed poorly with food.


Exocrine Pancreatic Insufficiency Epidemiological Segmentation 

The Epidemiological Segmentation of Exocrine Pancreatic Insufficiency in 7MM from 2017 to 2030 is segmented as:- 

  • Prevalence of Causative Indications of EPI
  • Prevalence of Exocrine Pancreatic Insufficiency


Exocrine Pancreatic Insufficiency Epidemiology 

  • The prevalence of Causative Indications of Exocrine Pancreatic Insufficiency was observed in Type II Diabetes Mellitus, and that was 67,892,836 in 7MM in 2017
  • The United States had the highest percentage of prevalent diagnosed and treated patients


Exocrine Pancreatic Insufficiency Market

The market for Exocrine Pancreatic Insufficiency in the United States in 2017 was USD 1,181.05 Million


Exocrine Pancreatic Insufficiency Market Drivers

  • Research and development strategies
  • Demands of advanced therapeutics for the treatment of EPI
  • Increasing global incidences of Exocrine Pancreatic Insufficiency
  • Delivery system strategies 

 

Exocrine Pancreatic Insufficiency Market Barriers

  • Lack of technological reach and advancements
  • Lack of confidence in diagnosis and management
  • Treatment failure to stimulate and follow society’s goals and requirements


Exocrine Pancreatic Insufficiency Emerging Drugs

The emerging drugs of the Exocrine Pancreatic Insufficiency market are 

  • Omeprazole
  • MS1819-SD

And many others. 


Exocrine Pancreatic Insufficiency Marketed Drugs

The marketed drugs of the Exocrine Pancreatic Insufficiency market are 

  1. Pertzye (pancrelipase)
  2. Creon (pancrelipase)/Lipacreon
  3. Zenpep (pancrelipase)
  4. Pancreaze
  5. Viokace (pancrelipase)
  6. RELiZORB
  7. Ultresa (pancrelipase)

And many others. 


Exocrine Pancreatic Insufficiency Key Players

The key players in the Exocrine Pancreatic Insufficiency market are

  • Chiesi Farmaceutici
  • AzurRx BioPharma
  • Digestive Care
  • AbbVie
  • Nestle
  • Janssen Pharmaceuticals
  • Aptalis Pharma/Forest Laboratories
  • Alcresta Therapeutics

And many others.